This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ober, B. T.
Right arrow Articles by Falkner, F. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ober, B. T.
Right arrow Articles by Falkner, F. G.

 Previous Article  |  Next Article 

Journal of Virology, August 2002, p. 7713-7723, Vol. 76, No. 15
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.15.7713-7723.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Immunogenicity and Safety of Defective Vaccinia Virus Lister: Comparison with Modified Vaccinia Virus Ankara

B. T. Ober, P. Brühl, M. Schmidt, V. Wieser, W. Gritschenberger, S. Coulibaly, H. Savidis-Dacho, M. Gerencer, and F. G. Falkner*

Biomedical Research Center, Baxter BioScience/Vaccine AG, A-2304 Orth/Donau, Austria

Received 14 February 2002/ Accepted 18 April 2002

Potent and safe vaccinia virus vectors inducing cell-mediated immunity are needed for clinical use. Replicating vaccinia viruses generally induce strong cell-mediated immunity; however, they may have severe adverse effects. As a vector for clinical use, we assessed the defective vaccinia virus system, in which deletion of an essential gene blocks viral replication, resulting in an infectious virus that does not multiply in the host. The vaccinia virus Lister/Elstree strain, used during worldwide smallpox eradication, was chosen as the parental virus. The immunogenicity and safety of the defective vaccinia virus Lister were evaluated without and with the inserted human p53 gene as a model and compared to parallel constructs based on modified vaccinia virus Ankara (MVA), the present "gold standard" of recombinant vaccinia viruses in clinical development. The defective viruses induced an efficient Th1-type immune response. Antibody and cytotoxic-T-cell responses were comparable to those induced by MVA. Safety of the defective Lister constructs could be demonstrated in vitro in cell culture as well as in vivo in immunodeficient SCID mice. Similar to MVA, the defective viruses were tolerated at doses four orders of magnitude higher than those of the wild-type Lister strain. While current nonreplicating vectors are produced mainly in primary chicken cells, defective vaccinia virus is produced in a permanent safety-tested cell line. Vaccines based on this system have the additional advantage of enhanced product safety. Therefore, a vector system was made which promises to be a valuable tool not only for immunotherapy for diseases such as cancer, human immunodeficiency virus infection, or malaria but also as a basis for a safer smallpox vaccine.

* Corresponding author. Mailing address: Baxter BioScience/Vaccine AG, Biomedical Research Center, Uferstrasse 15, A-2304 Orth/Donau, Austria. Phone: 43-1-20100-4232. Fax: 43-1-20100-4000. E-mail: falknef{at}baxter.com.

Journal of Virology, August 2002, p. 7713-7723, Vol. 76, No. 15
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.15.7713-7723.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Mayrhofer, J., Coulibaly, S., Hessel, A., Holzer, G. W., Schwendinger, M., Bruhl, P., Gerencer, M., Crowe, B. A., Shuo, S., Hong, W., Tan, Y. J., Dietrich, B., Sabarth, N., Savidis-Dacho, H., Kistner, O., Barrett, P. N., Falkner, F. G. (2009). Nonreplicating Vaccinia Virus Vectors Expressing the H5 Influenza Virus Hemagglutinin Produced in Modified Vero Cells Induce Robust Protection. J. Virol. 83: 5192-5203 [Abstract] [Full Text]  
  • Day, S. L., Ramshaw, I. A., Ramsay, A. J., Ranasinghe, C. (2008). Differential Effects of the Type I Interferons {alpha}4, {beta}, and {epsilon} on Antiviral Activity and Vaccine Efficacy. J. Immunol. 180: 7158-7166 [Abstract] [Full Text]  
  • Najera, J. L., Gomez, C. E., Domingo-Gil, E., Gherardi, M. M., Esteban, M. (2006). Cellular and Biochemical Differences between Two Attenuated Poxvirus Vaccine Candidates (MVA and NYVAC) and Role of the C7L Gene.. J. Virol. 80: 6033-6047 [Abstract] [Full Text]  
  • Someya, K., Ami, Y., Nakasone, T., Izumi, Y., Matsuo, K., Horibata, S., Xin, K.-Q., Yamamoto, H., Okuda, K., Yamamoto, N., Honda, M. (2006). Induction of Positive Cellular and Humoral Immune Responses by a Prime-Boost Vaccine Encoded with Simian Immunodeficiency Virus gag/pol. J. Immunol. 176: 1784-1795 [Abstract] [Full Text]  
  • Kidokoro, M., Tashiro, M., Shida, H. (2005). Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc. Natl. Acad. Sci. USA 102: 4152-4157 [Abstract] [Full Text]  
  • Legrand, F. A., Verardi, P. H., Chan, K. S., Peng, Y., Jones, L. A., Yilma, T. D. (2005). Vaccinia viruses with a serpin gene deletion and expressing IFN-{gamma} induce potent immune responses without detectable replication in vivo. Proc. Natl. Acad. Sci. USA 102: 2940-2945 [Abstract] [Full Text]  
  • Legrand, F. A., Verardi, P. H., Jones, L. A., Chan, K. S., Peng, Y., Yilma, T. D. (2004). Induction of Potent Humoral and Cell-Mediated Immune Responses by Attenuated Vaccinia Virus Vectors with Deleted Serpin Genes. J. Virol. 78: 2770-2779 [Abstract] [Full Text]  
  • Hodge, J. W., Poole, D. J., Aarts, W. M., Gomez Yafal, A., Gritz, L., Schlom, J. (2003). Modified Vaccinia Virus Ankara Recombinants Are as Potent as Vaccinia Recombinants in Diversified Prime and Boost Vaccine Regimens to Elicit Therapeutic Antitumor Responses. Cancer Res. 63: 7942-7949 [Abstract] [Full Text]  
  • Fischer, T., Planz, O., Stitz, L., Rziha, H.-J. (2003). Novel Recombinant Parapoxvirus Vectors Induce Protective Humoral and Cellular Immunity against Lethal Herpesvirus Challenge Infection in Mice. J. Virol. 77: 9312-9323 [Abstract] [Full Text]  
  • Konetschny, C., Holzer, G. W., Urban, C., Hammerle, T., Mayrhofer, J., Falkner, F. G. (2003). Generation of Transduction-Competent Retroviral Vectors by Infection with a Single Hybrid Vaccinia Virus. J. Virol. 77: 7017-7025 [Abstract] [Full Text]  
  • Belongia, E. A., Naleway, A. L. (2003). Smallpox Vaccine: The Good, the Bad, and the Ugly. Clin Med Res 1: 87-92 [Abstract] [Full Text]  
  • Espenschied, J., Lamont, J., Longmate, J., Pendas, S., Wang, Z., Diamond, D. J., Ellenhorn, J. D. I. (2003). CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model. J. Immunol. 170: 3401-3407 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»